Clinical trials: Caregiver Quality of Life
Monocarboxylate Transporter 8 (MCT8) Deficiency, Allan-Herndon-Dudley Syndrome
MCT8 Deficiency Caregiver Study
Caregivers face many responsibilities outside of their role as a friend or parent, which can lead to emotional, financial, social, and professional challenges.
- Trial name
- NCT06060197
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Rare Thyroid Therapeutics International AB
Parkinson's Disease
Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa
This multicenter, post marketing observational study (PMOS) was designed to evaluate the long-term effectiveness of levodopa/carbidopa intestinal gel (DUODOPA) on motor fluctuations (duration of OFF periods) in participants with…
- Trial name
- GREENFIELD (NCT01754129)
- Volunteers
- 148 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Multiple Sclerosis
An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their Caregivers
This is an observational, non controlled, non-interventional, multicentric, prospective study planned to be conducted in 450 subjects diagnosed with MS and their caregivers in 20 centres of Argentina.
- Trial name
- NCT01075737
- Where
- Argentina
- Volunteers
- 141 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Alzheimer Disease, Dementia
A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease
The purpose of this study is to evaluate the safety and effectiveness of two doses of galantamine (a drug for treating dementia) versus placebo in the treatment of patients with Alzheimer's disease.
- Trial name
- NCT00253188
- Testing
- galantamine hydrobromide
- Volunteers
- 653 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Duchenne Muscular Dystrophy (DMD)
DMD Voice: Qualitative Interviews With Patients and Caregivers
The purpose of this study is to understand DMD functional losses or abilities and their association with independence and quality of life from the perspective of individuals with DMD and/or and their caregivers.
- Trial name
- NCT06925269
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Red Nucleus Enterprise Solutions, LLC
Alzheimer Disease, Dementia
Assistive Technology and Reduced Caregiver Burden
The study investigated a six-week randomized controlled trial study in a small cohort of 16 family caregivers of individuals living with Alzheimer's disease and related dementias.
- Conditions
- Alzheimer Disease, Dementia, Caregiver Burden, Quality of Life
- Trial name
- ck (NCT05352529)
- Testing
- The MapHabit system, Dementia educational videos
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- MapHabit, Inc.
Type 1 Diabetes, T1D
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with…
- Conditions
- Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- DASH-Obesity (NCT07638345)
- Testing
- Adhera Caring Digital Program-Obesity (ACDP-O)
- Where
- Spain
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Quality of Life
Consequences of Respiratory Devices on Caregivers (CAP2)
The promoter of the study will conduct a monocentric cohort study that aim to evaluate the consequences of home respiratory devices on patient caregivers' quality of life.
- Trial name
- CAP2 (NCT04632836)
- Testing
- quality of life questionnaires
- Where
- France
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Asten Sante
Alzheimer Disease, Dementia
A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's Disease
The purpose of this study is to collect and compare information regarding the treatment and outcome of patients diagnosed with Alzheimer's disease who are receiving either drug or nondrug treatment.
- Conditions
- Alzheimer Disease, Dementia, Nervous System Diseases, Mental Disorders
- Trial name
- NCT00291421
- Volunteers
- 2,360 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy
Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)
The aim of this observational study is to assess humanistic burden among adults and children/adolescents with FSGS and IgAN as well as the burden and impact for patient care-partners in six countries (United States [US], United…
- Trial name
- HONUS (NCT05200871)
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 487 people
- Sponsor
- Travere Therapeutics, Inc.
Dementia, Alzheimer's Disease and Related Dementias
HomeCare Medication Management for People With Dementia
This study will evaluate whether the HomeCare medication management system can improve medication adherence and related outcomes for adults age 65 and older living with dementia, Alzheimer's disease, or related dementias.
- Trial name
- NCT07872072
- Testing
- HomeCare
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- HiDO Technologies
Advanced Parkinson's Disease
Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease
This study is a non-interventional post-marketing observational study (PMOS) of participants with advanced Parkinson's disease (PD) treated with Duodopa/Duopa in a routine clinical setting.
- Trial name
- DUOGLOBE (NCT02611713)
- Where
- 54 sites in United States, Australia and 8 more
- Volunteers
- 213 people
- Sponsor
- AbbVie
Alzheimer Disease, Dementia
A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease
The purpose of this study is to evaluate the safety and effectiveness of two doses of galantamine (a drug for treating dementia) versus placebo in the treatment of patients with Alzheimer's disease.
- Trial name
- NCT00253201
- Testing
- galantamine hydrobromide
- Volunteers
- 636 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.